Biosimilars In Spondyloarthritis - Dr. Rachel Tate Save

Hi, RheumNow. This is doctor Rachel Tate coming to you from my home in West Palm Beach, Florida, and I'm talking to you about EULAR twenty twenty and the virtual e congress that I hope you've been attending. And, again, check us out at roomnow.com for more information. Right now, I wanted to kinda go over a hot button topic and two particular abstracts that I found to be pretty interesting. So something that's come to light in the past few years biosimilars, and when we're talking about biosimilars, it's kind of nice to have a little bit of data behind it since we know they're similar and not bio identical.

So I'm going to tell you about one particular study first and then we'll come back to the other one, but this is abstract number six thirty two and it's a study out of India that looked at that looked at entanercept versus biosimilar etanercept in patients who had reactive arthritis. Now it's a smaller study, only about ninety four patients who had, reactive arthritis and were separated either into the etanercept group or 10 of them actually received biosimilar etanercept. And throughout this study, which was over two years, they found that at the one year follow-up for patients, no new safety signals in the biosimilar etanercept group and they also found that four out of ten had actually achieved drug free remission which is something we've come to expect for patients in general with reactive arthritis if we're lucky. So, the second study that I wanted to show you or tell you about today is out of Turkey. It's actually the results of the TREASURE study and this is abstract, number six fifty.

This again is a smaller study, two thirty one spondyloarthritis patients who were either receiving infliximab or biosimilar infliximab. And again, this study showed that biosimilar infliximab was just as efficacious and no new safety signals as its bio originator infliximab. So obviously, this is an ongoing kind of a hot button topic for us in rheumatology. I think we'll know more as more data is published and studied, but I think it's really interesting that we're actually looking at this and more than just rheumatoid arthritis. And so I don't want you to not have the option for all of our patients, and I think it's a really fun way to kind of discuss what's going on around the world instead of just talking about a global pandemic right now.

So again, this is Doctor. Rachel Tate presenting from West Palm Beach, Florida for ULAR twenty twenty in the e congress, and check us out on roomnow.com for all the latest and greatest. And I'll see you in just a few minutes. Thanks.